

Bianca D Santomasso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2118686/publications.pdf>

Version: 2024-02-01

41
papers

7,197
citations

257357

24
h-index

345118

36
g-index

42
all docs

42
docs citations

42
times ranked

7323
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 449-459.	13.9	1,951
2	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 625-638.	2.0	1,741
3	G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. <i>Nature</i> , 1998, 391, 86-89.	13.7	821
4	Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2018, 8, 958-971.	7.7	594
5	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
6	The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 433-444.	1.8	200
7	Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. <i>Blood Advances</i> , 2020, 4, 3776-3787.	2.5	162
8	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
9	Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 79.	2.8	137
10	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 387-405.	2.3	124
11	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. <i>Blood Advances</i> , 2020, 4, 676-686.	2.5	101
12	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
13	DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. <i>Blood Advances</i> , 2020, 4, 3024-3033.	2.5	75
14	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. <i>Blood Cancer Journal</i> , 2022, 12, 32.	2.8	73
15	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 817-835.	0.6	62
16	BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy. <i>Cancer Immunology Research</i> , 2019, 7, 1047-1053.	1.6	59
17	Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. <i>Blood Advances</i> , 2021, 5, 3397-3406.	2.5	59
18	Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. <i>Neuro-Oncology</i> , 2021, 23, 134-143.	0.6	56

#	ARTICLE	IF	CITATIONS
19	Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients. <i>Cancer Cell</i> , 2021, 39, 276-283.e3.	7.7	54
20	Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1759-1764.	0.5	49
21	Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. <i>Clinical Neurophysiology</i> , 2019, 130, 1440-1445.	0.7	44
22	MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors. <i>Neuro-Oncology</i> , 2019, 21, 1578-1586.	0.6	42
23	Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma. <i>Haematologica</i> , 2020, 106, 255-258.	1.7	38
24	A T cell receptor associated with naturally occurring human tumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19073-19078.	3.3	37
25	TÂcells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation. <i>European Journal of Immunology</i> , 2014, 44, 3240-3251.	1.6	31
26	Immune Checkpoint Inhibitor-Associated Optic Neuritis. <i>Ophthalmology</i> , 2020, 127, 1585-1589.	2.5	30
27	The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 233-240.	0.6	24
28	Tolerance to the Neuron-Specific Paraneoplastic HuD Antigen. <i>PLoS ONE</i> , 2009, 4, e5739.	1.1	24
29	A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma. <i>Blood</i> , 2021, 138, 96-96.	0.6	24
30	Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 426-445.	0.6	16
31	Anticancer Drugs and the Nervous System. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 732-764.	0.4	13
32	Neurotoxicity Biology and Management. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 126-133.	1.0	7
33	G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. <i>Nature</i> , 1998, 392, 210-210.	13.7	5
34	Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 1603-1603.	0.6	5
35	Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan. <i>CNS Oncology</i> , 2022, 11, .	1.2	4
36	T cells presenting viral antigens or autoantigens induce cytotoxic T cell anergy. <i>JCI Insight</i> , 2017, 2, .	2.3	3

#	ARTICLE	IF	CITATIONS
37	Reply. <i>Ophthalmology</i> , 2020, 127, e106-e107.	2.5	2
38	Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells. <i>Blood</i> , 2019, 134, 1947-1947.	0.6	2
39	Resource Utilization Early after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies. <i>Blood</i> , 2018, 132, 616-616.	0.6	1
40	Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T). <i>Blood</i> , 2019, 134, 4455-4455.	0.6	0
41	Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management. <i>Blood</i> , 2019, 134, 4458-4458.	0.6	0